Live data · NADAC + Part D CY24 · reviewed daily

Olmesartan Medoxomil and Hydrochlorothiazide

Thiazide Diuretic class · 10 generic manufacturers · 30 ANDAs filed at FDA.

First FDA approval2017-04-24
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.165/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.177
Across all dosage forms in distribution.
Highest NADAC
$0.209
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Olmesartan Medoxomil and Hydrochlorothiazide used for?

Olmesartan Medoxomil and Hydrochlorothiazide is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Olmesartan Medoxomil and Hydrochlorothiazide?

Yes. 30 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Olmesartan Medoxomil and Hydrochlorothiazide?

Across 329 Part D plans, Olmesartan Medoxomil and Hydrochlorothiazide averages $0.177/unit (NADAC). Lowest available: $0.165/unit. Highest in distribution: $0.209/unit.

Is Olmesartan Medoxomil and Hydrochlorothiazide on the FDA shortage list?

No. Olmesartan Medoxomil and Hydrochlorothiazide is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.